Miragen Therapeutics, Inc. (NASDAQ:MGEN) was founded in 2006 and is headquartered in Boulder, Colorado. It has 73 full-time employees. It is a clinical-stage biopharmaceutical company engaged in the discovery and development of proprietary RNA targeted therapies, with special attention MicroRNA and its role in disease, these areas have high unmet medical needs.
Miragen Therapeutics (MGEN):
Miragen Therapeutics’ three main product candidates include:
- cobomarsen-microRNA-155 inhibitor, a phase I clinical trial for the treatment of skin T-cell lymphoma.
- MRG-201-a substitute for microRNA-29, is at a low level in various pathological fibrotic conditions, including skin, heart, kidney, liver and lung fibrosis, and systemic sclerosis, currently in phase I clinical trials .
- MRG-110, a microRNA-92 inhibitor, is expressed in endothelial cells and has been shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia and skin trauma.
Miragen Therapeutics also developed:
MRG-107-miR-155 inhibitor, used to treat neuronal amyotrophic lateral sclerosis and other neurodegenerative diseases, including spinal cord injury.
Miragen Therapeutics has also developed preclinical candidate products for the treatment of various indications, including oncology, visual pathology, neurodegeneration and hearing loss.